Small-molecule ferroptosis inducers and sensitizers in anticancer drug discovery: medicinal chemistry, structure–activity relationships, and translational perspectives
Аннотация
Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation, proceeds independently of caspase activation and can remain effective in apoptosis-resistant and mesenchymal-like tumor populations, providing a pharmacologically addressable route around treatment resistance. Its regulation by enzymes, transporters and metabolic pathways, including glutathione peroxidase 4 (GPX4), the cystine/glutamate antiporter system xc⁻, ferroptosis suppressor protein 1 (FSP1), mitochondrial dihydroorotate dehydrogenase (DHODH), and iron and lipid metabolism, has created multiple starting points for small-molecule design. Unlike prior target-by-target surveys, this review cross-examines structure–activity relationships across these target classes to distinguish transferable design principles from mechanism-specific effects, and chemical probes from pharmacologically viable leads. Cross-target analysis shows that no single SAR pattern governs ferroptosis induction: scaffold requirements are target-dependent, linker length and rigidity produce mechanism-dependent effects, and electrophilic warheads require calibrated rather than maximal reactivity. Substituent modifications that improve one chemotype do not reliably transfer to another, while hybrid and multi-target compounds require evidence for target-specific contributions to activity. Translational evaluation reveals a recurring gap between cellular potency and the solubility, metabolic stability, systemic exposure, in vivo efficacy and tolerability required for development. Most compounds remain chemical probes, with PK/ADMET characterization, therapeutic-window data, off-target control and validated biomarkers for patient selection frequently lacking. Progress will therefore depend less on increasing ferroptotic potency than on converting active chemotypes into target-selective, pharmacokinetically viable and tolerable agents for biomarker-defined patient populations.